Cigna Medical Coverage Policy

Subject  Acne Procedures

Table of Contents
Coverage Policy .................................................. 1
General Background ........................................... 2
Coding/Billing Information ................................... 6
References .......................................................... 8

Hyperlink to Related Coverage Policies
Actinic Keratosis Treatments
Benign Skin Lesion Removal
Photodynamic Therapy for Dermatologic and Ocular Conditions
Phototherapy, Photochemotherapy and Excimer Laser Therapy for Dermatologic Conditions
Rosacea Procedures
Scar Revision

INSTRUCTIONS FOR USE
The following Coverage Policy applies to health benefit plans administered by Cigna companies. Coverage Policies are intended to provide guidance in interpreting certain standard Cigna benefit plans. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations. Proprietary information of Cigna. Copyright ©2014 Cigna

Coverage Policy

Coverage for the treatment of acne scarring is dependent on benefit plan language, may be subject to the provisions of a cosmetic and/or reconstructive surgery benefit, and may be governed by state mandates. Under many benefit plans, treatment of acne scarring is not covered when performed solely for the purpose of altering appearance or self-esteem or to treat psychological symptomatology or psychosocial complaints related to one’s appearance. Please refer to the applicable benefit plan language to determine benefit availability and the terms, conditions and limitations of coverage.

Please refer to the applicable pharmacy benefit to determine benefit availability and the terms and conditions of coverage for acne medications.

Cigna covers ANY of the following procedures as medically necessary for the treatment of active acne vulgaris:

- manual comedone extraction for noninflammatory comedones
- intralesional injections of corticosteroids (e.g., triamcinolone acetonide) for large nodules
- incision and drainage or opening and removal of cysts or pustules
- cryotherapy/cryosurgery (e.g., liquid nitrogen, acetone slush, carbon dioxide [CO₂]) for isolated inflammatory nodular lesions that fail to respond to topical and systemic medication therapy
• light cautery/electrocauterization or CO₂ laser for multiple macrocomedones (e.g., microcystic acne, whiteheads greater than 1.5 mm in diameter) that fail to respond to topical and systemic medication therapy

Cigna does not cover ANY of the following for the treatment of active acne vulgaris, when used alone or in combination, because each is considered experimental, investigational or unproven (this list may not be all-inclusive):

• chemical peels of any type (e.g., superficial, medium-depth and deep, as well as slush peels)
• phototherapy (including exposure to ultraviolet A or B; red, blue or red-blue light; Psoralens ultraviolet actinotherapy [PUVA]), laser or pulsed dye laser (PDL) therapy or photodynamic therapy (PDT)

Under many benefit plans, Cigna does not cover the treatment of acne scarring and other untoward cosmetic effects of acne, including but not limited to any of the following procedures, when used alone or in combination, because each is considered cosmetic in nature and not medically necessary:

• chemical exfoliation
• chemical peels of any type (e.g., superficial, medium-depth and deep peels, slush peels or chemabrasion)
• dermabrasion/dermaplaning/salabrasion (i.e., abrasion with salt)
• microdermabrasion/particulate resurfacing
• dermabrasion with selective freezing or icing (e.g., using ethyl chloride or Freon)
• dermaplaning
• collagen injections
• polymethyl-methacrylate microspheres with collagen (e.g., Artecoll®, Rofil Medical USA)
• gelatin matrix implant
• hyaluronic acid derivative fillers (e.g., Restylane®, Q-Med Inc.)
• autologous fat replacement
• punch biopsy elevation
• punch excision with or without full-thickness skin graft replacement
• electrodesiccation
• cryopeeling (i.e., superficial freezing of damaged skin) for small, widespread hypertrophic scars
• laser dermablation/laser abrasion using carbon dioxide or erbium;YAG lasers with or without follow-up cryotherapy
• cryotherapy/cryosurgery, when performed to treat acne scarring
• pulsed dye laser (PDL) treatment, when performed to treat acne scarring
• subcision or subcutaneous incision

General Background

Acne vulgaris is a chronic, inflammatory disease of the pilosebaceous follicles characterized by the formation of open and closed comedones (i.e., whiteheads and blackheads), erythematous papules and pustules, pseudocysts and nodules. It is generally a condition of adolescence involving the face, neck, upper trunk and upper arms. Factors responsible for the pathogenesis of acne vulgaris include increased sebum production, abnormality of the microbial flora, abnormal keratinization of sebaceous and follicular epithelium/ductal hypercornification, and inflammation.

The general principles of acne treatment include decreasing sebaceous gland secretion, correcting altered patterns of ductal hypercornification/abnormal keratinization, decreasing the population of the bacterium Propionibacterium acnes (P. acnes) and reducing inflammation. Acne vulgaris therapies range from over-the-counter and prescription topical medications to systemic therapy with antibiotics, retinoids and hormonal medications, to physical modalities, including surgery. Selection of an intervention is dependent upon the extent, severity and duration of the condition, as well as the type of lesions involved. Topical therapy is considered the appropriate first-line treatment for most patients with acne. Oral medications may be indicated when topical treatment fails.
Physical and Surgical Treatment
Physical modalities are an option when more conservative treatment fails to improve the condition. Therapies considered the standard of care include comedone removal; cryotherapy or superficial freezing with liquid nitrogen, acetone slush or carbon dioxide; and intraleosional steroid injections. While chemical peels are used in practice, their role in the treatment of active acne has not been established. Typically, incision and drainage of pustules is not used as a treatment option because of possible resultant scarring. Comedone removal, performed by a physician using a comedone extractor, can be used for the treatment of isolated noninflammatory comedones. Cryotherapy with carbon dioxide (CO2), liquid nitrogen, acetone slush, or solid carbon dioxide mixed with acetone can be used for isolated inflammatory nodular lesions; however, this method is typically reserved for patients who did not respond to more conventional therapy. Intraleosional injections of triamcinolone acetonide can be helpful in the treatment of large nodules. Removal of densely-packed, closed comedones, macrocomedones, and cysts by electrocautery or CO2 laser is generally reserved for patients in whom well-established topical or systemic therapy has failed.

Chemical Peels
A chemical peel involves the application of a chemical solution with the goal of producing controlled removal of layers of the epidermis and superficial dermis. Chemical peel solutions damage the outer layers of the skin and stimulate collagen formation, resulting in dermal regeneration and thereby improving the appearance of the skin. Alpha-hydroxy acids (AHAs), such as glycolic, lactic, or fruit acid, are used in superficial peeling to rejuvenate and resurface sun-damaged skin, soften the appearance of pores, treat fine wrinkles and reduce uneven pigmentation. Trichloroacetic acid (TCA) is used for medium-depth peeling to treat surface wrinkles and sun-damaged skin. Phenol, the strongest agent, is used in deep chemical peeling to diminish coarse facial wrinkles and correct pigment abnormalities.

Although chemical peels are generally performed for cosmetic purposes, it has been suggested that superficial or epidermal peels, using AHAs, may have a comedolytic effect on comedonal acne lesions by loosening follicular impaction and may be appropriate for individuals with widespread lesions for whom standard treatment has failed. However, the role of superficial peels in the overall management of patients with active acne has not been established through well-designed trials. While medium-depth and deep chemical peels are typically performed for cosmesis, they may also have an application in the treatment of patients with large numbers of actinic keratoses or other pre-malignant lesions. They are not, however, considered appropriate for active acne, as they have been shown to exacerbate the inflammation associated with acne.

Literature Review
A number of studies including case series and randomized uncontrolled trials with small patient populations (n=20–40) have evaluated the safety and effectiveness of superficial chemical peels for acne vulgaris and reported varying levels of improvement in active lesion counts (Levesque, et al., 2011; Kessler, et al., 2008; Cotellesa, et al., 2004). A systematic review (n=13 clinical trials) by Dreno et al. (2011) examined the evidence on superficial chemical peels for the treatment of acne. It was stated that the trials were primarily lower level evidence including case series and expert opinion and the majority of studies were uncontrolled, open label, with small numbers of patients. The available evidence was found to support the use of chemical peels in acne as all trials had generally favorable results. However trials differed in assessments of effectiveness, treatment regimens and patient populations. There were no studies of chemical peels identified that used an acne medication as a comparator (Dreno, et al., 2010).

There is insufficient evidence in the published, peer-reviewed scientific literature to support the use of any type of chemical peel in the treatment of active acne vulgaris. Randomized controlled trials (RCTs) directly comparing alpha-hydroxy acids with well-established treatments, such as topical retinoids, are lacking in the peer-reviewed medical literature. The use of chemical peels, when performed to alter or improve the appearance of the skin, is considered cosmetic in nature.

Phototherapy/Ultraviolet Radiation/Laser Therapy/Photodynamic Therapy
Light-based therapies, which include phototherapy (e.g., ultraviolet A or B; red, blue, or red-blue light; Psoralens ultraviolet actinotherapy [PUVA]), lasers, pulsed dye laser and photodynamic therapy (PDT), have been investigated for the treatment of acne vulgaris.
U.S. Food and Drug Administration (FDA): A number of phototherapy and laser devices have received U.S. Food and Drug Administration (FDA)-approval under the 510(k) process for the treatment of acne vulgaris, including the following:

- The Clareblend LED Probe (Clareblend Inc., Reno, Nevada) was approved in October 2008. The Clareblend Probe is a hand held device that utilizes light emitting diodes (LED) to provide LED light to the body. The output is pre-tuned to one wavelength with a narrow spectral bandwidth. Indications for the Clareblend device include the treatment of mild to moderate acne.
- The Aesthera Photopneumatic TM (PPx™) System (Aesthera Corporation, Pleasanton, CA) was granted marketing approval in September 2006. Intended uses for the PPx intense pulsed light system include the treatment of mild to moderate acne, including pustular acne, comedonal acne, and mild-to-moderate inflammatory acne (acne vulgaris). Based on this predicate device, the Isolaz™ Intense Pulsed Light System (Aesthera, Pleasanton, CA) was approved in January 2009 for similar indications.
- The Omnilux Blue (Photo Therapeutics Limited, Altrincham, Cheshire) received approval in June 2003. The device is a visible light source pre-tuned to one wavelength (i.e., 415 ± 5 nm) with a narrow spectral bandwidth. Indications for the Omnilux Blue include the treatment of moderate inflammatory acne vulgaris.
- The ClearLight™ System (CureLight Ltd., Or Akiva, Israel) was approved in August 2002 for the treatment of moderate, inflammatory acne vulgaris. This system is a high-intensity lamp that emits visible light in the violet-blue range.
- The Smoothbeam™ Diode Laser System (Candela, Wayland, MA) was approved for the treatment of mild to moderate inflammatory acne vulgaris in November 2000. This continuous-wave laser is controlled by an internal processor and contains a cooling device designed to reduce the discomfort associated with laser therapy.

Phototherapy: Exposure to ultraviolet radiation or other light (e.g., Ultraviolet B, Ultraviolet A, red light, blue light, mixed red-blue light and Psoralens Ultraviolet Actinotherapy) has been proposed as a treatment for acne vulgaris. Proponents of this treatment suggest that P. acnes produces porphyrins, which absorb light energy at the near-ultraviolet and blue-light spectrum (Kaminsky, 2003), leading to oxidation and ultimately destroying bacteria. It has also been theorized that exposure produces a comedolytic action. Potential short- and long-term side effects of repeated exposure to ultraviolet radiation include nausea, itching and burning of the affected area, premature aging and cancer of the skin, and eye damage.

The evidence assessing the safety and effectiveness of visible light therapy consists of nonrandomized comparative trials, split-face, double-blind controlled studies and few RCTs (Gold, et al., 2011; Ammad, et al., 2008; Lee, et al., 2006; Gold, et al., 2005; Morton, et al., 2005; Elman, et al., 2003; Papageorgiou, et al., 2000). Patient populations have ranged from 10─107. Studies have reported that phototherapy primarily with visible blue light resulted in mean reduction on inflammatory acne lesions ranging from 50─81%.

The available studies are limited by small sample sizes, and limited follow-up. Few studies have compared the effectiveness of visible light to that of established treatments for acne vulgaris. There is insufficient evidence to support the use of ultraviolet radiation or visible light for the treatment of acne vulgaris.

Laser Therapy: It has been proposed that laser treatment of acne vulgaris results in an area of thermal injury at the level of the dermis where the sebaceous glands are located. The evidence evaluating the safety and effectiveness of laser therapy for the acne includes randomized split-face trials and case series with sample sizes ranging from 13─27 and follow-up of four weeks to 12 months (Yeung, et al., 2009; Astner, et al., 2008; Konishi, et al., 2007; Wang, et al., 2006; Jih, et al., 2006). These studies have reported a reduction of 29%─76.1% in inflammatory acne lesion counts after laser treatment.

Although preliminary evidence suggests that laser therapy may result in improvement of acne symptoms, larger, well-designed studies with long term follow-up are needed to determine the role of this therapy in the treatment of acne vulgaris.

Pulsed Dye Laser (PDL) Therapy: PDL is designed to destroy small blood vessels under the first layer of skin without destroying the surrounding tissue and, as such, is typically used to treat vascular lesions. However, this
type of laser has been investigated as a treatment for mild-to-moderate acne. Several RCTs with small patient populations and short-term follow-up have assessed the safety and effectiveness of PDL for this indication.

A single-blinded RCT (n=80) by Karsai et al. (2010) compared the use of a proven topical treatment alone versus this treatment in combination with PDL. No substantial benefit of adjuvant PDL was found.

Leheta (2009) performed an RCT (n=45) that compared outcomes for three groups of patients whose acne vulgaris was treated with PDL, topical preparations or chemical peeling. In the short term a significant improvement of lesions within each group was reported, but there was no significant difference found between the three protocols after the treatment period. Remission in the follow-up period was found to be higher in the PDL group.

An RCT (n=45) by Sami et al. (2008) evaluated the effectiveness PDL, intense IPL and LED phototherapy and reported a ≥ 90% reduction in acne lesions treated with the PDL, 41.7% reduction in cases of IPL and 35.3% reduction for LED cases at one-month follow-up.

Haerdersdal et al. (2008b) found a significantly greater reduction in inflammatory lesions on MAL-LPDL-treated skin versus LPDL-treated skin at four weeks (p=0.003) and 12 weeks (p=0.004) with up to 80% reduction in inflammatory lesions. A single-blind, split-face RCT (n=40) by Orringer et al. (2004) reported that PDL did not result in significant improvement of facial acne. Seaton et al. (2003) compared PDL to sham in an RCT (n=41) and reported a 49% decrease in inflammatory lesions for patients who received PDL versus a reduction of 10% for those in the sham treatment group.

There is insufficient evidence in the published peer-reviewed medical literature to support the use of PDL for the treatment of acne vulgaris.

**Photodynamic Therapy (PDT):** PDT is characterized by the use of visible light in conjunction with the topical application of a photosensitizer such as 5-aminolevulinic acid (ALA) or methyl aminolaevulinate (MAL) that is intended to amplify the response to light therapy. Studies including case series and RCTs (n=10–44) have reported a 60%—80% improvement of acne lesions after treatment with ALA-PDT (Shaaban, et al., 2012; Jang, et al., 2011; Orringer, et al., 2010; Santos, et al., 2005; Pollack, et al., 2004; Taub, 2004; Goldman and Boyce, 2003) and MAL-PDT (Bissonnette, et al., 2010; Wiegell and Wulf, 2006; Horfelt, et al., 2006).

**Systematic Reviews:** A systematic review by Ingram and colleagues (2010) summarized clinical findings from RCTs (n=62 studies), systematic reviews (n=3) and a single guideline, all on the management of acne vulgaris. It was found that “PDT, phototherapy and laser therapy cannot be recommended universally for acne until minimal post-inflammatory pigmentation and longer-term benefit can be shown” (Ingram, et al., 2010).

Hamilton et al. (2009) reviewed 25 RCTs (n=694), 13 of light therapy and 12 of light therapy with light-activated topical cream (i.e., PDT). The trials were generally small with very short follow-up times. The review found limited or no benefit for light therapies alone. Study results could not be used in a meta-analysis because of the different wavelengths of light used across trials. Results of PDT trials were found to be more consistent and some short-term benefit was demonstrated in a meta-analysis of 3/12 trials. Overall, trials were limited by small sample sizes and short follow-up periods. There was a lack of studies comparing PDT with conventional treatment. Side effects of pain, erythema, and folliculitis followed by desquamation were reported (Hamilton, et al., 2009).

Haerdersdal et al. (2008a) reviewed 16 RCTs and three controlled trials (n=587) to assess the effects of optical treatments for acne vulgaris. The interventions included PDL, PDT, infrared lasers, broad-spectrum light sources and intense pulsed light. Most studies were intraindividual trials (12/19) with blinded response evaluations (12/19) and evaluated a short-term efficacy up to 12 weeks after treatment (17/19). Optical treatments were compared to standard intervention in two trials. Side-effects from optical treatments included pain, erythema, edema, crust, hyperpigmentation, pustular eruptions and were reported to be more intense for treatments combined with ALA or MAL. It was summarized that based on the available evidence, optical treatments may improve inflammatory acne on a short-term basis. The most consistent outcomes were found for PDT. The reviewers noted that further studies are needed comparing optical versus conventional treatments (Haerdersdal, et al., 2008a).
At this time, the published, peer-reviewed scientific literature contains insufficient supportive evidence for the use of PDT in the treatment of acne vulgaris.

**Professional Societies/Organizations**

The American Academy of Dermatology (AAD) guidelines for the management of acne vulgaris state that topical therapy and systemic antibiotics are a standard of care for the treatment of acne vulgaris. The effect of intrallesional injection with corticosteroids is also a well-established and recognized treatment for large inflammatory lesions. Although both glycolic acid-based and salicylic acid-based peeling preparations have been used in the treatment of this condition, there is very little evidence from clinical trials published in the peer-reviewed literature supporting the efficacy of peeling regimens. Additional research on the use of chemical peeling in the treatment of acne needs to be conducted in order to establish best practices for this modality. It is noted that the topic of light and laser therapy for the treatment of acne vulgaris will be addressed in a future guideline (Strauss, et al., 2007). An update to this guideline is anticipated for July 2014.

The Institute for Clinical Systems Improvements (ICSI) guideline for acne management states that the use of both a topical retinoid and a topical antibiotic has been found to be an effective course of treatment. The guideline further states that, although there continue to be numerous studies about light treatment for acne, including blue light and with and without pretreatment with topical medications, the evidence is inadequate at this time to make a recommendation about the efficacy and safety of these treatments (ICSI, 2006).

**Use Outside of the US**

A review article by Handog et al. (2012) stated that Asian acne patients have clinical features distinct from that of Caucasians, one being the lesser incidence of nodulocystic acne. Asians represent a rather challenging group of patients because of the greater tendency to develop post-inflammatory hyper pigmentation as sequelae of acne or any inflammation of the skin. The article also stated that although chemical peeling may be used in the management of acne and acne scarring, few studies have been conducted on Asian populations (Handog, et al., 2012).

The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and Ageing, and is responsible for regulating therapeutic goods including medicines, medical devices, blood and blood products. Any product for which therapeutic claims are made must be listed, registered or included in the Australian Register of Therapeutic Goods (ARTG) before it can be supplied in Australia. The Serenity® light therapy unit (Yperion Technology, Paris, France) is registered with the ARTG as of January 23, 2013. The device is based on light emitting diode technology and is intended to be used for skin rejuvenation, to combat visible signs of acne, stretch marks, and assist with accelerating the healing process of acne scars (TGA, 2013).

The British Association of Dermatologists guidelines for topical PDT state that “although PDT can improve inflammatory acne on the face and back, optimization of protocols, to sustain response while minimizing adverse effects, is awaited” (Morton, et al., 2008).

**Summary**

Established treatments for acne vulgaris include topical therapies (e.g., antimicrobials, retinoids) and systemic therapies such as antibiotics, isotretinoin and hormonal medications. For patients who develop significant side effects or fail to respond to these options, physical or surgical treatment (e.g., cryotherapy, intrallesional steroid injections, electrocauterization, comedone extraction) may be considered. Currently, there is insufficient evidence in the published, peer-reviewed scientific literature to support the use of light based therapies or chemical peels in the treatment of active acne vulgaris. Further well-designed, large-scale, randomized clinical trials are needed to determine the role of these modalities as an alternative to standard therapies. Even with appropriate treatment, scarring and other unwanted cosmetic changes, such as hyperpigmentation, are common complications of acne vulgaris. The goal of treating these sequelae is to improve appearance. Interventions such as dermabrasion, autologous fat replacement, or cryopeeling are generally considered to be cosmetic in nature when performed for acne scarring and are not appropriate for the treatment of active acne vulgaris.

---

**Coding/Billing Information**
Note: 1) This list of codes may not be all-inclusive.
2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement

Covered when medically necessary:

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>10040</td>
<td>Acne surgery (eg, marsupialization, opening or removal of multiple milia, comedones, cysts, pustules)</td>
</tr>
<tr>
<td>11900</td>
<td>Injection, intraintralosional; up to and including seven lesions</td>
</tr>
<tr>
<td>11901</td>
<td>Injection, intraintralosional; more than seven lesions</td>
</tr>
<tr>
<td>17110</td>
<td>Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettage), of benign lesions other than skin tags or cutaneous vascular lesions; up to 14 lesions</td>
</tr>
<tr>
<td>17111</td>
<td>Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettage), of benign lesions other than skin tags or cutaneous vascular lesions; 15 or more lesions</td>
</tr>
<tr>
<td>17340</td>
<td>Cryotherapy (CO2 slush, liquid N₂) for acne</td>
</tr>
</tbody>
</table>

Experimental/Investigational/Unproven/Not Covered when provided as a treatment for active acne vulgaris:

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>15788</td>
<td>Chemical peel, facial; epidermal</td>
</tr>
<tr>
<td>15789</td>
<td>Chemical peel, facial; dermal</td>
</tr>
<tr>
<td>15792</td>
<td>Chemical peel, nonfacial; epidermal</td>
</tr>
<tr>
<td>15793</td>
<td>Chemical peel, nonfacial; dermal</td>
</tr>
<tr>
<td>17360</td>
<td>Chemical exfoliation for acne (e.g., acne paste, acid)</td>
</tr>
<tr>
<td>96567</td>
<td>Photodynamic therapy by external application of light to destroy premalignant and/or malignant lesions of the skin and adjacent mucosa (eg, lip) by activation of photosensitive drug(s), each phototherapy exposure session</td>
</tr>
<tr>
<td>96900</td>
<td>Actinotherapy (ultraviolet light)</td>
</tr>
<tr>
<td>96910</td>
<td>Photochemotherapy; tar and ultraviolet B (Goeckerman treatment) or petrolatum and ultraviolet B</td>
</tr>
<tr>
<td>96912</td>
<td>Photochemotherapy; psoralen and ultraviolet A (PUVA)</td>
</tr>
</tbody>
</table>

HCPCS Codes | Description |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>E0691</td>
<td>Ultraviolet light therapy system, includes bulbs/lamps, timer and eye protection; treatment area two square feet or less</td>
</tr>
<tr>
<td>E0692</td>
<td>Ultraviolet light therapy system, includes bulbs/lamps, timer and eye protection, four foot panel</td>
</tr>
<tr>
<td>E0693</td>
<td>Ultraviolet light therapy system, includes bulbs/lamps, timer and eye protection, six foot panel</td>
</tr>
<tr>
<td>E0694</td>
<td>Ultraviolet multidirectional light therapy system in six foot cabinet, includes bulbs/lamps, timer and eye protection</td>
</tr>
<tr>
<td>J7308</td>
<td>Aminolevulinic acid HCL for topical administration, 20%, single unit dosage form (354 mg)</td>
</tr>
<tr>
<td>J7309</td>
<td>Methyl aminolevulinate (MAL) for topical administration, 16.8%, 1 g</td>
</tr>
</tbody>
</table>

Not Medically Necessary/Cosmetic/Not Covered when provided as a treatment for acne scarring:

<p>| CPT® Codes | Description |</p>
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>11100</td>
<td>Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; single lesion</td>
</tr>
<tr>
<td>11101</td>
<td>Biopsy of skin, subcutaneous tissue and/or mucous membrane (including simple closure), unless otherwise listed; each separate/additional lesion (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>11950</td>
<td>Subcutaneous injection of filling material (eg, collagen); 1 cc or less</td>
</tr>
<tr>
<td>11951</td>
<td>Subcutaneous injection of filling material (eg, collagen); 1.1 to 5.0 cc</td>
</tr>
<tr>
<td>11952</td>
<td>Subcutaneous injection of filling material (eg, collagen); 5.1 to 10.0 cc</td>
</tr>
<tr>
<td>11954</td>
<td>Subcutaneous injection of filling material (eg, collagen); over 10.0 cc</td>
</tr>
<tr>
<td>15780</td>
<td>Dermabrasion; total face (eg, for acne scarring, fine wrinkling, rhytids, general keratosis)</td>
</tr>
<tr>
<td>15781</td>
<td>Dermabrasion; segmental, face</td>
</tr>
<tr>
<td>15782</td>
<td>Dermabrasion; regional, other than face</td>
</tr>
<tr>
<td>15783</td>
<td>Dermabrasion; superficial, any site (eg, tattoo removal)</td>
</tr>
<tr>
<td>15788</td>
<td>Chemical peel, facial; epidermal</td>
</tr>
<tr>
<td>15789</td>
<td>Chemical peel, facial; dermal</td>
</tr>
<tr>
<td>15792</td>
<td>Chemical peel, nonfacial; epidermal</td>
</tr>
<tr>
<td>15793</td>
<td>Chemical peel, nonfacial; dermal</td>
</tr>
<tr>
<td>17360</td>
<td>Chemical exfoliation for acne (e.g., acne paste, acid)</td>
</tr>
</tbody>
</table>


References


Page 9 of 11
Coverage Policy Number: 0043


